# Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

Source: https://onco.cc/trials/nct06855277/  
OnCo record `nct06855277` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing AAA817 in prostate cancer, now recruiting.

## Summary

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC is a phase 3 interventional study registered as NCT06855277, led by Novartis Pharmaceuticals, and recruiting on the registry. Official title: A Phase III, Open-label, Multi-centre, Randomised Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer. Planned enrolment is 940 participants (estimated). The study started in 2025-07-01 and primary completion is expected in 2028-09-29. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Also known as: AcTFirst
- Tags: ctgov-ingest
- Registry id: NCT06855277
- Phase: 3
- Setting: A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 940

## Sources

- ClinicalTrials.gov NCT06855277: https://clinicaltrials.gov/study/NCT06855277

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [AAA817](https://onco.cc/drugs/aaa817/)
- companies: [Novartis](https://onco.cc/companies/novartis/)

---
JSON: https://onco.cc/api/v1/entities/nct06855277.json